

Gain insight into the latest treatments for Glaucoma and Dry-Eye Disease at Ophthalmic Drugs Conference 2021

SMi Group reports: Exploring the unique challenges and latest breakthroughs in ocular drug development and delivery

LONDON, LONDON BRIDGE , UNITED KINGDOM, July 19, 2021

[/EINPresswire.com/](https://www.einpresswire.com/) -- The global [ophthalmic](#) drug market is forecast to surpass \$60 billion USD by 2025 with increasing focus from the industry on alternative delivery approaches and improving the effectiveness of the current repertoire of drugs in order to grow away from intravitreal injections and other surgical approaches to ocular therapy.

A promotional graphic for the Ophthalmic Drugs Conference 2021. It features a dark background with a glowing blue and pink eye diagram on the left. The text on the right reads "SMi Group presents the 4th Annual... OPTHALMIC DRUGS" in large, bold, pink letters. Below this, the dates "22 - 23 NOV 2021" are displayed in white. At the bottom, the website "www.ophthalmicdrugs.com" is written in pink. The entire graphic is framed by a thin white border.

SMi Group presents the 4th Annual...
OPHTHALMIC DRUGS
22 - 23
NOV
2021
www.ophthalmicdrugs.com
Ophthalmic Drugs Conference 2021

With this in mind the upcoming conference in November will offer peer-to-peer networking opportunities with leaders in the ophthalmic sphere, from Heads of Drug Development and Senior Directors of Ophthalmology, all the way to academic forerunners in the research into ocular therapy.

Download the brochure to see full agenda and speaker line-up:
www.ophthalmicdrugs.com/einpr3

Benefits of attending:

- Gain insight into the latest treatments for [Glaucoma](#) and [Dry-Eye](#) Disease from Aerie Pharmaceuticals
- Examine the challenges of designing the right drug for topical drug delivery to the retina with Ocuterra Therapeutics
- Understand the advancements in treatments for inherited retinal diseases from ProQR
- Explore the design and characteristics of a durable local ocular formulation with forwardvue

pharma

- Discuss patient centricity as a driver for drug delivery innovation in ophthalmology with Roche
- Discover a novel target for Geographic Atrophy and Diabetic Retinopathy with InflammX Therapeutics
- Review the hidden and unmet clinical need of Diabetic Macular Ischemia with Boehringer Ingelheim
- Receive key updates on ocular gene therapy from SparingVision
- Uncover the clinical development and regulatory landscape for ophthalmic products in the UK and Europe from Bayer

Register online www.opthalmicdrugs.com/einpr3

Proudly Sponsored by Experimentica & TALLC

For media queries please contact Jinna Sidhu at hsidhu@smi-online.co.uk or call +44 (0)20 7827 6088

--END--

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses, and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Jinna Sidhu
SMi Group
02078276088
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/546651099>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.